Australian Family Physician
Australian Family Physician


Volume 39, Issue 9, September 2010

Oral hypoglycaemics A review of the evidence

Stephen M Twigg Patrick J Phillips
Download article
Cite this article    BIBTEX    REFER    RIS

The range of oral hypoglycaemic agents (OHAs) has increased from one insulin sensitiser (metformin) and one class of insulin secretagogues (sulphonylureas) with the addition of further class of insulin secretagogues (glitinides), a further class of insulin sensitisers (glitazones) and two new classes: an alpha glycosidase inhibitor and glucagon-like peptide agents. Recent data has influenced the recommended sequence and usage of OHAs and glycaemic targets.
This article reviews the recent evidence in type 2 diabetes about the pros and cons of oral hypoglycaemic agents and the benefits and costs of intensive glycaemic control. It suggests a stepwise approach to glycaemic control with OHAs according to the evidence base currently available.

Download the PDF for the full article.

Download article PDF


Australian Family Physician RACGP

Printed from Australian Family Physician - https://www.racgp.org.au/afp/2010/september/oral-hypoglycaemics-a-review-of-the-evidence
© The Australian College of General Practitioners www.racgp.org.au